NYSE: ELANElanco Animal Health Inc Stock
$22.76+0.11 (+0.49%)
Updated Dec 30, 2025
ELAN Price
$22.76
Fair Value Price
N/A
Market Cap
$11.31B
52 Week Low
$8.02
52 Week High
$23.70
P/E
325.14x
P/B
1.68x
P/S
2.18x
PEG
2.08x
Dividend Yield
N/A
Revenue
$4.59B
Earnings
$36.00M
Gross Margin
55%
Operating Margin
3.7%
Profit Margin
0.8%
Debt to Equity
1.01
Operating Cash Flow
$629M
Beta
1.17
Next Earnings
Feb 25, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ELAN Overview
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for companion and food animals. It offers companion animal disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production. The company sells its products to third-party distributors; veterinarians; and food animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. The company has a research and development collaboration with AgBiome, Inc. to develop nutritional health products for swine; and strategic alliance with the Purdue University and Purdue Research Foundation. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ELAN's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
A
ELAN
Ranked#12 of 55
Ranked#12 of 55
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $47.13 | A | |
| $3.33 | A | |
| $35.73 | A |
Be the first to know about important ELAN news, forecast changes, insider trades & much more!
ELAN News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ELAN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ELAN ($22.76) is trading above its intrinsic value of $4.49, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ELAN is poor value based on its earnings relative to its share price (325.14x), compared to the US market average (44.23x)
P/E vs Market Valuation
ELAN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more ELAN due diligence checks available for Premium users.
Valuation
ELAN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
325.14x
Industry
-50.04x
Market
44.23x
ELAN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ELAN is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
ELAN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.68x
Industry
2.37x
ELAN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ELAN price to earnings growth (PEG)
For valuing profitable companies with growth potential
ELAN is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
ELAN's financial health
Profit margin
Revenue
$1.1B
Net Income
-$34.0M
Profit Margin
-3%
ELAN's Earnings (EBIT) of $170.00M... subscribe to Premium to read more.
Interest Coverage Financials
ELAN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$13.6B
Liabilities
$6.8B
Debt to equity
1.01
ELAN's short-term assets ($3.49B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELAN's long-term liabilities ($5.35B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELAN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ELAN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$219.0M
Investing
-$101.0M
Financing
-$153.0M
ELAN's operating cash flow ($629.00M)... subscribe to Premium to read more.
Debt Coverage Financials
ELAN vs Pharmaceutical Stocks
Elanco Animal Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.